Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically targeted radiotherapy for multiple myeloma.

David Dingli1, Rosa Maria Diaz, Elizabeth R Bergert

  • 1Mayo Clinic and Foundation, Rochester, MN, USA.

Blood
|March 22, 2003
PubMed
Summary

This study developed a targeted lentiviral vector for multiple myeloma therapy. The vector specifically targets myeloma cells, enabling expression of a gene that concentrates radioiodine, leading to tumor eradication in mice.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Blood advances·2026
Same author

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.

Blood cancer journal·2026
Same author

Time-Related Burden of Treatment With Parenterally Administered Complement Inhibitors: A Mixed Methods Observational Study Exploring Experiences among Patients With Paroxysmal Nocturnal Hemoglobinuria.

Health science reports·2026
Same author

Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.

Bone marrow transplantation·2026
Same author

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

American journal of hematology·2026

Area of Science:

  • Oncology
  • Gene Therapy
  • Molecular Biology

Background:

  • Multiple myeloma is an incurable plasma cell cancer.
  • Current therapies like radiation cause significant toxicity.
  • Genetic approaches are needed for targeted myeloma treatment.

Purpose of the Study:

  • To develop a self-inactivating (SIN) lentiviral vector for specific transgene expression in multiple myeloma cells.
  • To evaluate the therapeutic potential of targeting myeloma cells with the human sodium-iodide symporter (hNIS) gene.

Main Methods:

  • Constructed a SIN lentivector utilizing immunoglobulin promoter and enhancer elements.
  • Transduced myeloma cell lines and assessed enhanced green fluorescent protein (EGFP) expression.
  • Introduced the hNIS gene into myeloma cells and evaluated radioiodine uptake.

Related Experiment Videos

  • Treated myeloma xenografts in mice with iodine-131 (131I) after hNIS expression.

    • Main Results:

    • Lentivector efficiently transduced myeloma cell lines (30%-90%) with high-level EGFP expression.
    • EGFP expression was specific to myeloma cells, unlike CMV promoter/enhancer.
    • Myeloma cells expressing hNIS concentrated radioiodine up to 18-fold.
    • hNIS-expressing tumor xenografts were successfully imaged with 123I and eradicated by 131I therapy without recurrence.

    Conclusions:

    • Lentivectors can be transcriptionally targeted for myeloma cells.
    • The hNIS gene combined with 131I shows promise for multiple myeloma therapy.
    • Further exploration of this gene therapy approach for myeloma is warranted.